CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round ...

For decades, the pharmaceutical industry has discussed moving away from in vivo models in preclinical research. Now, it’s more than a conversation. The FDA’s roadmap for reducing animal testing, ...

From idea, to lab, to clinic, to approval—it's a long and expensive process to bring a drug to market. It also rarely succeeds. Northeastern University researchers You Wu and Lei Xie are proposing ...

For decades, animal models have been the gold standard for preclinical testing of potential drugs. Yet, even the best animal models are not perfect. For example, small rodent species with engrafted ...

Today, The Jackson Laboratory (JAX) announced a bold initiative to improve that trajectory, powered by an up to $30 million contract from the Advanced Research Projects Agency for Health (ARPA-H) ...

Organoid-on-chip technology merges patient-derived organoids with microfluidic engineering to recreate human physiology and predict drug responses with high precision. This innovation is reshaping ...

In the UK, there was a case where TGN1412, an immunotherapy under development, triggered a cytokine storm within hours of administration to humans, leading to multiple organ failure. Another example, ...

Forbes contributors publish independent expert analyses and insights. Greg Licholai writes and teaches about innovation in healthcare. In an era where artificial intelligence (AI) is transforming ...

Typically, bone marrow research relies heavily on animal models and oversimplified cell cultures in the laboratory. Now, researchers from the Department of Biomedicine at the University of Basel and ...

The Food and Drug Administration and National Institutes of Health held a joint workshop July 7 on reducing animal testing in research, strikingly announcing that “NIH will no longer seek proposals ...